Exhibit 10.5 PRO-PHARMACEUTICALS, INC. CONSULTING AGREEMENT (David H. Smith) CONSULTING AGREEMENT entered into as of January 16, 2003 (the "Effective Date"), by and between Pro-Pharmaceuticals, Inc., a Nevada corporation having an address of 189 Wells...Consulting Agreement • March 31st, 2003 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • November 20th, 2015 • Galectin Therapeutics Inc • Pharmaceutical preparations
This Registration Rights Agreement (this “Agreement”) is made and entered into as of November 19, 2015, between Galectin Therapeutics, Inc., a Nevada corporation (the “Company”), and each of the several purchasers signatory hereto (each such purchaser, a “Purchaser” and, collectively, the “Purchasers”).
EXHIBIT 10.1 PRO-PHARMACEUTICALS, INC. EMPLOYMENT AGREEMENT EMPLOYMENT AGREEMENT, made this 6th day of May 2003, with an effective date as herewith set forth, between Pro-Pharmaceuticals, Inc., a Nevada corporation having an address of 189 Wells...Employment Agreement • October 4th, 2007 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • February 15th, 2006 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of February , 2006 among Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
COMMON STOCK PURCHASE WARRANT GALECTIN THERAPEUTICS, INC.Common Stock Purchase Warrant • November 20th, 2015 • Galectin Therapeutics Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after May , 2016 (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Galectin Therapeutics, Inc., a Nevada corporation (the “Company”), up to shares (as subject to adjustment hereunder, the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
Exhibit 10.2 STOCK EXCHANGE AGREEMENTStock Exchange Agreement • June 13th, 2001 • Pro Pharmaceuticals Inc • Minnesota
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • September 27th, 2016 • Galectin Therapeutics Inc • Pharmaceutical preparations • Delaware
This Securities Purchase Agreement (this “Agreement”) is dated as of September 22, 2016, between Galectin Therapeutics, Inc., a Nevada corporation (the “Company”), and 10X Fund, L.P., a Delaware limited partnership (the “Purchaser”).
EXHIBIT 10.1Employment Agreement • January 23rd, 2009 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • November 20th, 2015 • Galectin Therapeutics Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of November 19, 2015, between Galectin Therapeutics, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
REGISTRATION RIGHTS AGREEMENTRegistration Rights Agreement • June 20th, 2007 • Pro Pharmaceuticals Inc • Pharmaceutical preparations
This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser (the “Purchase Agreement”).
WARRANT AGREEMENTWarrant Agreement • March 20th, 2019 • Galectin Therapeutics Inc • Pharmaceutical preparations • New York
THIS WARRANT AGREEMENT (this “Agreement”), dated as of [•], 2019, is entered into by and between Galectin Therapeutics, Inc., a Nevada corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (the “Warrant Agent”).
THIS WARRANT AND THE SECURITIES ISSUABLE UPON EXERCISE HEREOF HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), OR ANY OTHER SECURITIES LAWS AND MAY NOT BE OFFERED FOR SALE, SOLD, TRANSFERRED, ASSIGNED,...Warrant Agreement • February 2nd, 2009 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • New York
This DEALER-MANAGER WARRANT (this “Warrant”) of Pro-Pharmaceuticals, Inc., a corporation duly organized and validly existing under the laws of the State of Nevada (the “Company”), is being issued pursuant to that certain Dealer Manager Agreement, dated as of February ___, 2009, by and between the Company and Maxim Group LLC (the “Dealer Manager”) relating to an offering by the Company of rights (the “Offering”) to subscribe for common stock, par value $0.001 per share (the “Common Stock”). The Dealer Manager has acted as dealer-manager for the Offering.
COMMON STOCK PURCHASE WARRANT To Purchase Shares of Common Stock of Pro- Pharmaceuticals, Inc.Security Agreement • April 9th, 2004 • Pro Pharmaceuticals Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT CERTIFIES that, for value received, (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after April 8, 2004 (the “Initial Exercise Date”) and on or prior to the close of business on April 7, 2009 [in the case of Rodman & Renshaw, Inc., April 7, 2007] (the “Termination Date” and the period from the Initial Exercise Date until the Termination Date, the “Exercise Period”)) but not thereafter, to subscribe for and purchase from Pro-Pharmaceuticals, Inc., a corporation incorporated in the State of Nevada (the “Company”), up to shares (the “Warrant Shares”) of Common Stock, of the Company (the “Common Stock”). The purchase price of one share of Common Stock (the “Exercise Price”) under this Warrant shall be $5.30, subject to adjustment hereunder. The Exercise Price and the number of Warrant Shares for which the Warrant is exercisable shall be subject to adjustment
7% CONVERTIBLE DEBENTURE DUE FEBRUARY , 2008Convertible Security Agreement • February 15th, 2006 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS CONVERTIBLE DEBENTURE is one of a series of duly authorized and validly issued 7% Convertible Debentures of Pro-Pharmaceuticals, Inc., a Nevada corporation, having its principal place of business at 189 Wells Avenue, Newton, Massachusetts 02459 (the “Company”), designated as its 7% Convertible Debenture, due February , 2008 (this debenture, the “Debenture” and collectively with the other such series of debentures, the “Debentures”).
COMMON STOCK PURCHASE WARRANT To Purchase Shares of Common Stock of Pro- Pharmaceuticals, Inc.Security Agreement • August 16th, 2004 • Pro Pharmaceuticals Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT CERTIFIES that, for value received, (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the six month anniversary of August 13, 2004 (the “Initial Exercise Date”) and on or prior to the close of business on August 12, 2009 (the “Termination Date” and the period from the Initial Exercise Date until the Termination Date, the “Exercise Period”)) but not thereafter, to subscribe for and purchase from Pro-Pharmaceuticals, Inc., a corporation incorporated in the State of Nevada (the “Company”), up to shares (the “Warrant Shares”) of Common Stock, of the Company (the “Common Stock”). The purchase price of one share of Common Stock (the “Exercise Price”) under this Warrant shall be $4.20, subject to adjustment hereunder. The Exercise Price and the number of Warrant Shares for which the Warrant is exercisable shall be subject to adjustment as provided herein. C
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • June 20th, 2007 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of June 19, 2007, between Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”).
OFFICE LEASE AGREEMENT BETWEEN NS 7/57 ACQUISITION LLC, a Delaware limited liability company (“LANDLORD”) AND PRO-PHARMACEUTICALS, INC., a Nevada corporation (“TENANT”)Office Lease Agreement • May 5th, 2006 • Pro Pharmaceuticals Inc • Pharmaceutical preparations
Re: Commencement Letter with respect to that certain Lease dated as of the day of , , by and between , a , as Landlord, and , as Tenant, for rentable square feet on the floor of the Building located at , Massachusetts, .
PRO-PHARMACEUTICALS, INC. RESTRICTED STOCK AGREEMENT FORRestricted Stock Agreement • March 30th, 2009 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
PLACEMENT AGENCY AGREEMENTPlacement Agency Agreement • November 20th, 2015 • Galectin Therapeutics Inc • Pharmaceutical preparations • New York
Galectin Therapeutics Inc., a Nevada corporation (the “Company”), proposes, subject to the terms and conditions stated herein, to issue and sell, through the Roth Capital Partners, LLC (the “Placement Agent”) as placement agent, securities of the Company consisting of shares (“Shares”) of the Company’s common stock (“Common Stock”), par value $0.001 per share, and warrants to purchase shares of Common Stock (“Warrants”, and collectively with the Shares, the “Securities”), directly to various investors (the “Investors”) pursuant to a securities purchase agreement (the “Purchase Agreement”).
GALECTIN THERAPEUTICS INC. Common Stock (par value $0.001 per share) At Market Issuance Sales AgreementAt Market Issuance Sales Agreement • May 19th, 2017 • Galectin Therapeutics Inc • Pharmaceutical preparations • New York
Galectin Therapeutics Inc., a Nevada corporation (the “Company”), confirms its agreement (this “Agreement”), with FBR Capital Markets & Co. (“FBR”), as follows:
10,435,005 of Units GALECTIN THERAPEUTICS INC. Units Consisting of Two Shares of Common Stock and One Warrant to Purchase One Share of Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • March 23rd, 2012 • Galectin Therapeutics Inc • Pharmaceutical preparations • New York
COMMON STOCK PURCHASE WARRANT PRO-PHARMACEUTICALS, INC.Security Agreement • June 20th, 2007 • Pro Pharmaceuticals Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after , 2007 (the “Initial Exercise Date”) and on or prior to the close of business on the seven year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to shares (the “Warrant Shares”) of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • August 16th, 2004 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of August 12, 2004, among Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the purchasers identified on the signature pages hereto (each a “Purchaser” and collectively the “Purchasers”); and
GALECTIN THERAPEUTICS INC. FORM OF WARRANT AGREEMENTWarrant Agreement • March 23rd, 2012 • Galectin Therapeutics Inc • Pharmaceutical preparations • New York
WARRANT AGREEMENT (this “Agreement”) entered into as of March 28, 2012 (the “Issuance Date”), between Galectin Therapeutics Inc., a Nevada corporation, with offices at 7 Wells Avenue, Newton, Massachusetts 02459 (the “Company”), and Continental Stock Transfer & Trust Co., with offices at 17 Battery Place, 8th Floor, New York, New York 10004 (the “Warrant Agent”).
FORM OF SUBSCRIPTION AGENT AGREEMENTSubscription Agent Agreement • February 2nd, 2009 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • New York
THIS SUBSCRIPTION AGENT AGREEMENT (“Agreement”) between Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and Continental Stock Transfer & Trust Company, a New York corporation (“Continental”), is dated as of February [ ], 2009.
PRO-PHARMACEUTICALS, INC. INCENTIVE STOCK OPTION AGREEMENT FOR AgreementIncentive Stock Option Agreement • March 30th, 2009 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
PRO-PHARMACEUTICALS, INC.Employment Agreement • December 21st, 2007 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
EMPLOYMENT AGREEMENT, as amended and restated this 20th day of December 2007, between Pro-Pharmaceuticals, Inc., a Nevada Corporation having an address of 7 Wells Avenue, Newton, Massachusetts 02459 (the “Company”), and, Anthony D. Squeglia, an individual residing at 20 Spyglass Point Circle, Bedford, New Hampshire 03110, (the “Employee”).
GALECTIN THERAPEUTICS, INC. AMENDED EMPLOYMENT AGREEMENT July 1, 2012Employment Agreement • July 25th, 2012 • Galectin Therapeutics Inc • Pharmaceutical preparations • Massachusetts
This Amended Employment Agreement (“Agreement”) is entered into this 19th day of July 2012, is intended to be effective as of July 1, 2012 (the “Effective Date”), and is by and between GALECTIN THERAPEUTICS INC., a Nevada corporation, having its principal executive office at 7 Wells Avenue, Suite 34, Newton, Massachusetts (the “Company”), and MAUREEN E. FOLEY, an individual residing at 46 Pond Circle, Jamaica Plain, Massachusetts (the “Executive”).
SECURITIES PURCHASE AGREEMENTSecurities Purchase Agreement • October 10th, 2003 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • New York
This Securities Purchase Agreement (this “Agreement”) is dated as of October 2, 2003, among Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), and the purchasers identified on the signature pages hereto (each a “Purchaser” and collectively the “Purchasers”); and
COMMON STOCK PURCHASE WARRANT To Purchase Shares of Common Stock of PRO- PHARMACEUTICALS, INC.Security Agreement • February 15th, 2006 • Pro Pharmaceuticals Inc • Pharmaceutical preparations
THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, (the “Holder”), is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the 181st day following the date hereof (the “Initial Exercise Date”) and on or prior to the close of business on the five year anniversary of the Initial Exercise Date (the “Termination Date”) but not thereafter, to subscribe for and purchase from Pro-Pharmaceuticals, Inc., a Nevada corporation (the “Company”), up to shares (the “Warrant Shares”) of Common Stock, par value $.001 per share, of the Company (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b).
PRO-PHARMACEUTICALS, INC. NON-QUALIFIED STOCK OPTION AGREEMENT FOR AgreementNon-Qualified Stock Option Agreement • March 30th, 2009 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • Massachusetts
SUBJECT TO LEGAL REVIEW AND COMMITMENT COMMITTEE APPROVALPlacement Agent Agreement • February 15th, 2008 • Pro Pharmaceuticals Inc • Pharmaceutical preparations • New York
EMPLOYMENT AGREEMENTEmployment Agreement • August 1st, 2024 • Galectin Therapeutics Inc • Pharmaceutical preparations • Georgia
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made August 1, 2024, by and between Galectin Therapeutics Inc., a Nevada corporation (the “Company”), and Khurram Jamil, MD, an individual residing in the State of Pennsylvania (“Executive”).
GALECTIN THERAPEUTICS INC. EMPLOYMENT AGREEMENTEmployment Agreement • July 5th, 2011 • Galectin Therapeutics Inc • Pharmaceutical preparations • Massachusetts
This Employment Agreement (“Agreement”) is entered into as of this 28th day of June 2011 (the “Effective Date”) by and between GALECTIN THERAPEUTICS INC., a Nevada corporation, having its principal Executive office at 7 Wells Avenue, Suite 34, Newton, Massachusetts 02459 (the “Company”), and JAMES C. CZIRR, an individual residing at 425 Janish Drive, Sandpoint, Idaho 83864 (the “Executive”).
EMPLOYMENT AGREEMENTEmployment Agreement • August 14th, 2013 • Galectin Therapeutics Inc • Pharmaceutical preparations • Georgia
THIS EMPLOYMENT AGREEMENT (this “Agreement”) is made this 20th day of June, 2013, by and between Galectin Therapeutics Inc., a Nevada corporation (the “Company”), and Jack Callicutt, an individual residing in the State of Georgia (“Executive”).
